NORML Files to Participate in DEA Marijuana Rescheduling Hearing

NORML Files for Hearing Participation Under APA Rules

NORML submitted its participation request to the DEA on May 26, invoking Administrative Procedure Act provisions that allow interested parties to join formal rulemaking hearings. The organization is seeking intervenor status in the rescheduling proceeding, which the DEA announced in August 2024 following a Department of Health and Human Services recommendation to move marijuana from Schedule I to Schedule III under 21 U.S.C. § 812.

The motion argues that NORML's membership—estimated at more than 150,000 individuals—constitutes a directly affected class that federal administrative law requires agencies to consider. Agencies conducting formal hearings must allow participation by parties whose interests are substantially affected by the outcome, per 5 U.S.C. § 556.

NORML has participated in prior DEA rescheduling petitions, including the 2011 and 2016 proceedings that resulted in denial. This time is different. The agency initiated rescheduling on its own motion rather than responding to a citizen petition.

Consumer Representation Absent from Current Participant List

The DEA's preliminary participant roster includes pharmaceutical companies, state attorneys general, and medical research institutions, but no organizations representing cannabis consumers or patients. NORML's filing notes that existing participants skew heavily toward law enforcement, medical gatekeepers, and commercial interests.

That gap leaves unrepresented the population most directly affected by marijuana's legal status: the estimated 55 million Americans who used cannabis in 2023, according to the National Survey on Drug Use and Health. Schedule III status wouldn't legalize recreational use, but it would affect federal research barriers, tax treatment under 26 U.S.C. § 280E, and criminal sentencing guidelines.

Administrative law judges (ALJs) typically grant intervenor status when applicants demonstrate a concrete interest distinct from the general public. NORML's motion cites its 54-year history of advocacy and its organizational mission as evidence of standing.

Hearing Timeline and Next Procedural Steps

The DEA hasn't yet published a final hearing schedule, but the Administrative Procedure Act requires the agency to rule on participation motions within 30 days of filing. If granted, NORML would gain the right to present witnesses, cross-examine government and opposing witnesses, and submit written briefs to the ALJ.

The rescheduling hearing is expected to convene in late 2026 or early 2027, with the ALJ's recommended decision then going to the DEA Administrator for a final rule—a process that typically takes 6-12 months. For full background on this story, see the CannIntel topic hub on DEA rescheduling.

Watch for the DEA's ruling on NORML's motion, due by late June 2026. If the agency denies standing, NORML could appeal to federal court under the APA's judicial review provisions.